Establishment of a population pharmacokinetic model for linezolid in neonates with sepsis
FENG Zong-Tai, TANG Lian, YANG Zu-Ming, GAO Chu-Chu, LI Jia-Hui, CAI Yan, DUAN Lu-Fen
Department of Pharmacy, Suzhou Municipal Hospital/Affiliated Suzhou Hospital of Nanjing Medical University/Gusu School of Nanjing Medical University, Suzhou, Jiangsu 215002, China
Abstract：Objective To establish the pharmacokinetic model of linezolid in neonates, and to optimize the administration regimen. Methods A prospective study was conducted among 64 neonates with sepsis who received linezolid as anti-infective therapy, and liquid chromatography-tandem mass spectrometry was used to measure the plasma concentration of the drug. Clinical data were collected, and nonlinear mixed effects modeling was used to establish a population pharmacokinetic (PPK) model. Monte Carlo simulation and evaluation was performed for the optimal administration regimen of children with different features. Results The pharmacokinetic properties of linezolid in neonates could be described by a single-compartment model with primary elimination, and the population typical values for apparent volume of distribution and clearance rate were 0.79 L and 0.34 L/h, respectively. The results of goodness of fit, visualization verification, and the Bootstrap method showed that the model was robust with reliable results of parameter estimation and prediction. Monte Carlo simulation results showed that the optimal administration regimen for linezolid in neonates was as follows: 6 mg/kg, q8h, at 28 weeks of gestational age (GA); 8 mg/kg, q8h, at 32 weeks of GA; 9 mg/kg, q8h, at 34-37 weeks of GA; 11 mg/kg, q8h, at 40 weeks of GA. Conclusions The PPK model established in this study can provide a reference for individual administration of linezolid in neonates. GA and body weight at the time of administration are significant influencing factors for the clearance rate of linezolid in neonates.
FENG Zong-Tai,TANG Lian,YANG Zu-Ming et al. Establishment of a population pharmacokinetic model for linezolid in neonates with sepsis[J]. CJCP, 2024, 26(11): 1162-1168.
3 Nelson JD, Bradley JS, Kimberlin DW, et al. 2021 Nelsons Pediatric Antimicrobial Therapy[M]. 27th ed. Itasca: American Academy of Pediatrics, 2021.
Liu P, Capitano B, Stein A, et al. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis[J]. BMC Nephrol, 2017, 18(1): 168. PMID: 28532398. PMCID: PMC5440938. DOI: 10.1186/s12882-017-0581-y.
Kocher S, Müller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review[J]. Int J Antimicrob Agents, 2010, 36(2): 106-110. PMID: 20605418. DOI: 10.1016/j.ijantimicag.2010.03.030.
Cojutti PG, Merelli M, Bassetti M, et al. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study[J]. J Antimicrob Chemother, 2019, 74(12): 3588-3595. PMID: 31504570. DOI: 10.1093/jac/dkz374.
Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents[J]. Pediatr Clin North Am, 1987, 34(3): 571-590. PMID: 3588043. DOI: 10.1016/s0031-3955(16)36251-4.
Sicard M, Launay E, Caillon J, et al. Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants[J]. Eur J Clin Pharmacol, 2015, 71(5): 611-615. PMID: 25740677. DOI: 10.1007/s00228-015-1813-3.
Thibault C, Kassir N, Goyer I, et al. Population pharmacokinetics of intravenous linezolid in premature infants[J]. Pediatr Infect Dis J, 2019, 38(1): 82-88. PMID: 29634620. DOI: 10.1097/INF.0000000000002067.
